NEUROCRINE BIOSCIENCES INC (NBIX)
$154.06-$1.86 (-1.19%) Today
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 22 | 116,636 | $19.35M |
| Option exercise | 30 | 212,436 | |
| Tax withholding / forfeiture | 1 | 1,733 | |
| Bona-fide gift | 2 | 4,850 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
89 Form 4 filings on record, the earliest from Oct 7, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Gary A. Lyons - Director | Option exercise | Common Stock | 15,000 | $47.89 | $718K | |
| Gary A. Lyons - Director | Open-market sale | Common Stock | 15,000 | $152.61 | $2.29M | |
| Gary A. Lyons - Director | Option exercise | Non-Qualified Stock Option | 15,000 | $0.00 | - | |
 Jude Onyia - Officer | Option exercise | Common Stock | 4,426 | $0.00 | - | |
| Jude Onyia - Officer | Tax withholding / forfeiture | Common Stock | 2,248 | $152.16 | $342K | |
| Jude Onyia - Officer | Option exercise | Restricted Stock Unit | 4,426 | $0.00 | - | |
| Eric Benevich - Officer | Option exercise | Common Stock | 5,970 | $35.99 | $215K | |
| Eric Benevich - Officer | Open-market sale | Common Stock | 5,970 | $151.74 | $906K | |
| Eric Benevich - Officer | Option exercise | Incentive Stock Option | 5,970 | $0.00 | - | |
| George J. Morrow - Director | Option exercise | Common Stock | 15,000 | $47.89 | $718K | |
| George J. Morrow - Director | Open-market sale | Common Stock | 15,000 | $143.37 | $2.15M | |
| George J. Morrow - Director | Option exercise | Non-Qualified Stock Option | 15,000 | $0.00 | - | |
 William H. Rastetter - Director | Option exercise | Common Stock | 18,000 | $47.89 | $862K | |
| William H. Rastetter - Director | Open-market sale | Common Stock | 18,000 | $151.82 | $2.73M | |
| William H. Rastetter - Director | Option exercise | Non-Qualified Stock Option | 18,000 | $0.00 | - | |
| Kyle Gano - Officer | Option exercise | Restricted Stock Unit | 613 | $0.00 | - | |
| Kyle Gano - Officer | Option exercise | Common Stock | 613 | $0.00 | - | |
| Kyle Gano - Officer | Open-market sale | Common Stock | 300 | $141.97 | $43K | |
| Jude Onyia - Officer | Gift | Common Stock | 1,470 | $0.00 | - | |
| Stephen A. Sherwin - Director | Gift | Common Stock | 1,000 | $0.00 | - | |
 Kevin Charles Gorman - Director | Option exercise | Common Stock | 106,322 | $35.99 | $3.83M | |
| Kevin Charles Gorman - Director | Open-market sale | Common Stock | 106,322 | $126.41 | $13.44M | |
| Kevin Charles Gorman - Director | Option exercise | Non-Qualified Stock Option | 106,322 | $0.00 | - | |
| Jude Onyia - Officer | Gift | Common Stock | 3,116 | $0.00 | - | |
| Ingrid Delaet - Officer | Option exercise | Common Stock | 457 | $79.02 | $36K | |
| Ingrid Delaet - Officer | Open-market sale | Common Stock | 457 | $135.00 | $62K | |
| Ingrid Delaet - Officer | Option exercise | Non-Qualified Stock Option | 457 | $0.00 | - | |
| Jude Onyia - Officer | Option exercise | Common Stock | 59,819 | $84.74 | $5.07M | |
| Jude Onyia - Officer | Open-market sale | Common Stock | 59,819 | $130.46 | $7.80M | |
| Jude Onyia - Officer | Option exercise | Non-Qualified Stock Option | 59,819 | $0.00 | - | |
| Jude Onyia - Officer | Option exercise | Common Stock | 20,362 | $84.74 | $1.73M | |
| Jude Onyia - Officer | Open-market sale | Common Stock | 20,362 | $130.13 | $2.65M | |
| Jude Onyia - Officer | Option exercise | Non-Qualified Stock Option | 20,362 | $0.00 | - | |
| Kevin Charles Gorman - Director | Open-market sale | Common Stock | 9,613 | $120.38 | $1.16M | |
| Stephen A. Sherwin - Director | Option exercise | Common Stock | 2,869 | $0.00 | - | |
| Stephen A. Sherwin - Director | Grant or award | Restricted Stock Unit | 3,318 | $0.00 | - | |
| Stephen A. Sherwin - Director | Option exercise | Restricted Stock Unit | 2,869 | $0.00 | - | |
| George J. Morrow - Director | Option exercise | Common Stock | 2,869 | $0.00 | - | |
| George J. Morrow - Director | Grant or award | Restricted Stock Unit | 3,318 | $0.00 | - | |
| George J. Morrow - Director | Option exercise | Restricted Stock Unit | 2,869 | $0.00 | - | |
| William H. Rastetter - Director | Option exercise | Common Stock | 2,869 | $0.00 | - | |
| William H. Rastetter - Director | Grant or award | Restricted Stock Unit | 3,318 | $0.00 | - | |
| William H. Rastetter - Director | Option exercise | Restricted Stock Unit | 2,869 | $0.00 | - | |
| Kevin Charles Gorman - Director | Grant or award | Non-Qualified Stock Option | 6,610 | $0.00 | - | |
| Christine A. Poon - Director | Option exercise | Common Stock | 1,435 | $0.00 | - | |
| Christine A. Poon - Director | Grant or award | Restricted Stock Unit | 3,318 | $0.00 | - | |
| Christine A. Poon - Director | Option exercise | Restricted Stock Unit | 1,435 | $0.00 | - | |
| Richard F. Pops - Director | Option exercise | Common Stock | 2,869 | $0.00 | - | |
| Richard F. Pops - Director | Grant or award | Restricted Stock Unit | 3,318 | $0.00 | - | |
| Richard F. Pops - Director | Option exercise | Restricted Stock Unit | 2,869 | $0.00 | - | |
| Gary A. Lyons - Director | Option exercise | Common Stock | 1,435 | $0.00 | - | |
| Gary A. Lyons - Director | Grant or award | Restricted Stock Unit | 1,659 | $0.00 | - | |
| Gary A. Lyons - Director | Grant or award | Non-Qualified Stock Option | 3,305 | $0.00 | - | |
| Gary A. Lyons - Director | Option exercise | Restricted Stock Unit | 1,435 | $0.00 | - | |
| William H. Rastetter - Director | Option exercise | Common Stock | 30,000 | $42.76 | $1.28M | |
| William H. Rastetter - Director | Open-market sale | Common Stock | 30,000 | $110.20 | $3.31M | |
| William H. Rastetter - Director | Option exercise | Non-Qualified Stock Option | 30,000 | $0.00 | - | |
| Ingrid Delaet - Officer | Option exercise | Common Stock | 1,091 | $79.02 | $86K | |
| Ingrid Delaet - Officer | Open-market sale | Common Stock | 1,091 | $135.00 | $147K | |
| Ingrid Delaet - Officer | Option exercise | Non-Qualified Stock Option | 1,091 | $0.00 | - | |
| Eiry Roberts - Officer | Grant or award | Restricted Stock Unit | 5,487 | $0.00 | - | |
| Eiry Roberts - Officer | Grant or award | Stock Option | 27,770 | $0.00 | - | |
| Jude Onyia - Officer | Option exercise | Common Stock | 4,426 | $0.00 | - | |
| Jude Onyia - Officer | Open-market sale | Common Stock | 2,331 | $126.29 | $294K | |
| Jude Onyia - Officer | Option exercise | Restricted Stock Unit | 4,426 | $0.00 | - | |
| Eiry Roberts - Officer | Option exercise | Common Stock | 5,140 | $77.81 | $400K | |
| Eiry Roberts - Officer | Option exercise | Common Stock | 1,233 | $81.05 | $100K | |
| Eiry Roberts - Officer | Option exercise | Common Stock | 971 | $102.90 | $100K | |
| Eiry Roberts - Officer | Option exercise | Common Stock | 1 | $79.02 | $79 | |
| Eiry Roberts - Officer | Option exercise | Incentive Stock Option | 5,140 | $0.00 | - | |
| Eiry Roberts - Officer | Option exercise | Incentive Stock Option | 1,233 | $0.00 | - | |
| Eiry Roberts - Officer | Option exercise | Incentive Stock Option | 971 | $0.00 | - | |
| Eiry Roberts - Officer | Option exercise | Incentive Stock Option | 1 | $0.00 | - | |
| Stephen A. Sherwin - Director | Gift | Common Stock | 2,000 | $0.00 | - | |
| Kyle Gano - Officer | Grant or award | Restricted Stock Unit | 2,455 | $0.00 | - | |
| Kyle Gano - Officer | Grant or award | Stock Option | 13,344 | $0.00 | - | |
| David W. Boyer - Officer | Open-market sale | Common Stock | 1,295 | $113.66 | $147K |
This is as far as the anonymous view goes. Create a free account for all 89 NBIX filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR | |
| - | - | - | - | View on EDGAR |
NEUROCRINE BIOSCIENCES INC (NBIX) had 13 insider filings in the last 90 days, with the most recent on 2026-08-05. The full record for NBIX runs to 89 Form 4 filings, the earliest from 2024-10-07. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of NBIX were filed in the last 90 days.
22 insider sales of NBIX were filed in the last 90 days, totaling $19.35M.
This page tracks NBIX Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add NBIX to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
